2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1979

Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis
Abstract Number: 1980

Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France
Abstract Number: 1981

Increased Extracellular Water Measured By Bioimpedance Analysis in Polymyalgia Rheumatica Patients – Sign of Volume Overload
Abstract Number: 1982

Sonographic Scoring of the Synovial Components in the Shoulder Revealed That Shoulder Synovitis in PMR Patients Is Milder Than That in Elderly-Onset RA Patients with PMR-like Onset
Abstract Number: 1983

Interspinous Bursitis Evaluation By Ultrasound Is Very Useful for Diagnosis of Polymyalgia Rheumatica
Abstract Number: 1984

Incidence and Intensity of 18fdg Uptake on Whole Body PET/CT in Patients with Polymyalgia Rheumatica
Abstract Number: 1985

Abnormal B-Cell Distribution Is Improved By Tocilizumab Monotherapy in Patients with Polymyalgia Rheumatica
Abstract Number: 1986

Clinical Efficacy of Tocilizumab in Polymyalgia Rheumatica: An OPEN-Label Study.
Abstract Number: 1987

Dramatic Efficacy of Tocilizumab As First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study
Abstract Number: 1988

Efficacy and Safety of Mizoribine for Polymyalgia Rheumatica: Analysis of 47 Cases
Abstract Number: 1989

Treatment of Refractory Non-Infectious Aortitis: Tocilizumab Compared to Antitnf Alfa Agents. Multicenter Study of 44 Patients
Abstract Number: 1990

Corticosteroid Use in Idiopathic Aortitis: A Systematic Review
Abstract Number: 1991

Large Vessel Involvement By IgG4-Related Disease
Abstract Number: 1992

Plasma Endothelin-1 Parallels the Vasoconstriction Phase in Reversible Cerebral Vasoconstriction Syndrome
Abstract Number: 1993

Imaging Findings of Cerebral Amyloid Angiopathy, Abeta-Related Angiitis (ABRA) and Cerebral Amyloid Angiopathy-Related Inflammation: A Single Institution 25 Year Experience

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].